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Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158 /1078 INTRODUCTION 11 Multiple myeloma (MM) is a clonal expansion of plasma cells (PCs) in the bone marrow (BM), 12 where they proliferate and acquire resistance to apoptosis and drugs (1). MM angiogenesis results 13 from interactions between PCs and BM microenvironment cells, and is a constant hallmark of 14 disease progression since it correlates with tumor growth, relapse and drug resistance (2). The 15 angiogenesis is enhanced in MM patients compared to those with monoclonal gammopathy of 16 undetermined significance (MGUS) and normal controls (3); and it correlates with prognosis (4).
17
MM remains an incurable malignancy, despite important advances in conventional as well as high- Hepatocyte growth factor (HGF)/scatter factor (SF) is a potent angiogenic cytokine. Bussolino et al. 22 first showed that HGF vividly induces endothelial cell (ECs) proliferation and migration in vitro by 23 triggering their specific tirosine kinase receptor mesenchymal-epithelial transition factor (cMET), 24 and angiogenesis in vivo using the rodent cornea assay (6) . It also enhances the expression of other 25 angiogenic factors, including vascular endothelial growth factor (VEGF) and its receptors, and 26 Research.
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Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158 /1078 suppresses the expression of thrombospondin 1, an endogenous angiogenesis inhibitor (7) . Aberrant 1 HGF/cMET pathway activation has been described in both solid (8) and blood tumors (9) in which 2 it triggers several signaling pathways, including Src/FAK, p120/STAT3, PI3K/Akt and Ras/MEK, 3 which results in cell proliferation, migration, invasion, and resistance to apoptosis. The HGF/cMET 4 pathway is thus important for tumor growth, angiogenesis, and metastatic spread. 5 The HGF/cMET pathway is involved in the MM pathogenesis. Coexpression of HGF and cMET 6 has been observed in MM PCs, implying the existence of an autocrine loop (9, 10). Since BM 7 stromal cells (BMSCs) produce HGF (11), a paracrine stimulation of PCs within their 8 microenvironment may occur, and provide mitogenic, migratory and morphogenic effects (9). HGF 9 levels are significantly increased in peripheral and BM blood of MM patients at diagnosis compared 10 with healthy controls, and represent a negative prognostic factor (12). We have shown that the 11 HGF/cMET pathway is constitutively activated in PCs from relapsed and resistant patients, and that 12 it mediates the multidrug resistance (10). We have also shown a therapeutic activity of SU11274, a 13 specific adenosine triphosphate-competitive small-molecule cMET inhibitor in a MM xenograft 14 model (10). Furthermore, SU11274 is able to inhibit cMET phosphorylation and cMET-dependent 15 motility, invasion and proliferation in preclinical models of lung (13) and ovarian (14) and control ECs were harvested and cultured as described (16). 6 MMECs, MGECs and control ECs (1×10 6 cells/mL) were cultured for 24 h in serum-free medium 7 (SFM) 1% glutamine, and their conditioned media (CM) were prepared (16). HGF was quantified in 8 the CM by an ELISA (Quantikine ® Human HGF, R&D Systems, Inc., Minneapolis, MN, USA).
5

ELISA, immunoprecipitation, western blot, and real time reverse transcriptase (RT)-PCR
9
Protein lysates from all the ECs types (7×10 5 cells/sample) were incubated with an anti-cMET 10 antibody (Ab) (Cell Signaling Technology, Danvers, MA, USA), then antigen-Ab complexes 11 immunoprecipitated by Protein G/agarose (Sepharose®, Sigma-Aldrich, St Louis, MO, USA). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158 /1078 cytofluorimeter and the FACSDiva software (Becton Dickinson-BD, San Jose, CA, USA). Negative 1 controls were stained with isotype-matched irrelevant antibodies (BD). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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1 Angiogenesis on Matrigel. Two×10 4 MMECs/well were seeded in triplicate on Matrigel-coated 2 (BD) 48-well plates in SFM alone (positive control), or added with the neutralizing Abs, or with 3 SU11274 and/or bortezomib or lenalidomide. After 18 h the skeletonization of the mesh was 4 followed by measurement of mesh areas and vessel length in three randomly-chosen ×200 fields on 5 an EVOS digital inverted microscope (Euroclone) (18). Three different doses of SU11274 (0.1, 0.5, 6 and 1 µmol/L), bortezomib (7.5, 10, and 20 nmol/L) and lenalidomide (0.5, 0.25, and 1.75 µmol/L) 7 were singularly tested in the Matrigel assay. The antiangiogenic potency of the drug associations 8 was assessed by combining the highest dose of SU11274 with the highest dose of bortezomib or 9 lenalidomide.
10
"Wound" healing. Confluent MMECs on fibronectin (10 μg/mL)-coated (Sigma-Aldrich) 6 cm 2 11 dishes were scraped as a "wound" with a pipette tip, and left to move into the wound for 24 h in 12 SFM alone (control), or added with the neutralizing Abs or with SU11274. Cells were fixed, and 13 counted in at least three randomly chosen ×10 wound fields on the EVOS microscope (17). 14 Chemotaxis. By using the Boyden microchamber assay (16), 1×10 5 MMECs/well were seeded in 15 triplicate on the upper compartment of the chamber, exposed to the neutralizing Abs or SU11274, 16 and left to migrate towards DMEM with 1.5% fetal calf serum (negative control) or added with 17 VEGF (10 ng/mL, Sigma Chemical Co.) and FGF-2 (10 ng/mL, Peprotech Inc., Rocky Hill, NJ, 18 USA) (positive control) in the lower compartment. After 8 h at 37°C, the migrated cells were fixed, 19 stained (Snabb-Diff Kit, Labex AB, Helsingborg, Sweden), and counted on 3-4 ×400 20 fields/membrane using the EVOS microscope. In vivo chorioallantoic membrane (CAM) assay 24 Fertilized white Leghorn chicken eggs were incubated at 37°C at constant humidity (23). On day 3, 25 the shell was opened and 2-to-3 mL of albumen removed to detach the CAM. On day 8, the CAMs Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158/1078-0432.CCR-14-0847 were implanted with 1 mm 3 sterilized gelatin sponges (Gelfoam Upjohn Co., Kalamazoo, MI, USA) 1 loaded with SFM alone (negative control) or with the CM of MMECs untreated (positive control) or 2 treated with SU11274 alone or added with bortezomib and/or lenalidomide. On day 12, the 3 angiogenic response was evaluated as the number of vessels converging toward the sponge at ×50 4 and photographed in ovo by a stereomicroscope (Olympus Italia Srl, Segrate, Milan, Italy). ~4-fold more vs control ECs (P<0.01; Fig. 1A ). Accordingly, MMECs secreted ~2.5-fold more 11 HGF than MGECs (P<0.03) and ~12-fold more than control ECs (P<0.01) in a 24 h serum-free 12 medium (SFM) culture (Fig. 1B, left panel) . Similarly, immunoprecipitated total cMET protein was 13 ~3-fold more in MMECs vs MGECs and control ECs (P<0.01; Fig. 1B, right panel) . The activation 14 of cMET in MMECs was assessed by western blot and optical density (OD) of p-cMET: it was ~4-15 fold more vs MGECs and control ECs (P<0.01; Fig. 1B, right panel) . FACS analysis (Fig. 1C ) 16 showed high variability in cMET and p-cMET expression among 1 st diagnosed MM patients (20 ± 17 10% double positive MMECs), while refractory and relapsed patients gave substantially higher 18 expression (60 ± 15% and 80 ± 20% vs 9 ± 7% MGECs and 2 ± 1% control ECs; P<0.001; Fig.   19 1C). Immunofluorescence studies (Fig. 1D ) confirmed these data, and showed a cytoplasmatic 20 colocalization of both molecules in MMECs, but not in MGECs and control ECs. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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The simultaneous expression of both HGF and cMET, and the evidence of a constitutive p-cMET 1 expression in MMECs suggest that a HGF/cMET autocrine loop is operative in these cells. To 2 validate this hypothesis, p-cMET was evaluated by flow cytometry in all ECs types starved in SFM 3 for 24 h ( Fig. 2A) : while the p-cMET/cMET double positive cells decreased in MGECs and control 4 ECs, they persisted in MMECs (18% vs 20% in a 1 st diagnosed, 72% vs 80% in a refractory, and 5 70% vs 79% in a relapsed representative patients; Fig. 2A ). Treatment of MMECs from refractory 6 and relapsed patients with anti-HGF (80 ng/µL) or anti-cMET (40 ng/µL) neutralizing Abs reduced 7 sizeably the p-cMET expression ( Fig. 2B) . Similar data were obtained in 1 st diagnosed patients 8 (data not shown).
9
The evidence that MMECs unchange the p-cMET expression on starvation (i.e., in absence of 10 external stimulation), together with its inhibition by anti-HGF and anti-cMET Abs suggest that an 11 autocrine HGF/cMET pathway is operative in MMECs of active patients.
13
The HGF/cMET autocrine loop mediates MMECs migration and angiogenesis 14 We next investigated whether the HGF/cMET pathway regulates the MMECs angiogenic activities.
15
A 24 h treatment with anti-HGF and anti-cMET Abs in SFM did not modify neither MMECs 16 viability (Fig. 3A) , nor apoptosis, nor proliferation ( Supplementary Fig. S1A; PI=1 ). Data were 17 confirmed at 72 h (not shown). However, the spontaneous MMECs migration into the "wound" 18 lowered by 78% and 80% (as average) with anti-HGF or anti-cMET Abs, and by 82% with both 19 (migrated cells: 20 ± 3, 18 ± 2, and 16 ± 2 vs 88 ± 15 in untreated MMECs; P<0.001; Fig. 3B ).
20
Similarly, in the Boyden microchambers, the MMECs migratory activity towards VEGF+FGF-2 21 (both 10 ng/mL) as chemoattractants was inhibited by 40%, 37%, and 45% (P<0.01; Fig. 3C , left 22 panel). The lack of differences between each single and combined treatments in absence of external 23 stimulation further confirms the existence of an autocrine HGF/cMET loop in MMECs.
24
MMECs adhesion and spreading were inhibited by 30% with the anti-cMET Ab (P<0.03; Fig. 3C , 25 middle and right panels) but not with anti-HGF Ab, perhaps because an intracrine secretion of HGF Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158/1078-0432.CCR-14-0847 stimulating the intracellular moiety of cMET (24) takes place in MMECs, and contributes to these 1 cell functions.
2
MMECs are able to spontaneously spread and form a closely knit capillary network when seeded on 3 Matrigel surface due to their overangiogenic phenotype (Fig. 3D) (16) . The anti-HGF and anti-4 cMET Abs significantly inhibited the angiogenic network, since they reduced the mesh areas by 5 48% and 55%, respectively, and the vessel length by 47% and 57%, respectively, vs untreated cells.
6
When Abs were combined both areas and length were inhibited approximately at the same extent, 7 which further corroborates the existence of an autocrine HGF/cMET loop in MMECs. 8 Overall data suggest that HGF/cMET pathway regulates MMECs migratory activities, and that it is 9 implicated in the whole MM angiogenesis. 
Effects of cMET inhibition by SU11274 in vitro 12
MMECs were treated with SU11274 0.1-10 µmol/L: no effect on cell viability, except for the 13 highest (toxic) dose (Fig. 4A ), nor on cell apoptosis, nor proliferation ( Supplementary Fig. S1B ; 14 PI=1) was observed at 24 h. Similar data were obtained at 72 h (not shown). Of note, 0.5 and 1 15 µmol/L were able to decrease the p-cMET expression respectively by 23% and 40% 16 ( Supplementary Fig. S2A ).
17
Much in the same way as the Abs, SU11274 reduced dose dependently both spontaneous and 18 chemotactic migration: at 0.5 and 1 µmol/L, the former ("wound" assay; Fig. 4B ) lowered 19 respectively by 60% and 87% (as average) vs untreated cells (migrated cells: 40 ± 7 and 14 ± 4 vs 20 90 ± 11; P<0.001); the latter by 36% and 70% (P<0.01; Fig. 4C, left panel) . SU11274 impacted 21 dose dependently with MMECs attachment to and spread on fibronectin: at 1 µmol/L, these cell 22 activities were reduced respectively by 42% and 30% (P<0.01 and P<0.03; Fig. 4C , middle and 23 right panels). SU11274 was able to inhibit dose dependently the whole MMECs angiogenesis: 0.5 24 and 1 µmol/L reduced the mesh areas respectively by 58% and 80%; the vessel length by 61% and 25 83% vs untreatred cells ( Supplementary Fig. S2B ).
26
Research.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158/1078-0432.CCR-14-0847 1 µmol/L), bortezomib (7.5 nmol/L [20]), and lenalidomide (1.75 µmol/L [17]) gave an overlapping 2 antiangiogenic effect since inhibited the mesh areas by 48%, 42% and 45%, respectively; the vessel 3 length by 53%, 41% and 43% (Fig. 4D) . When SU11274 was combined with bortezomib or 4 lenalidomide, it gave statistically significant antiangiogenesis: inhibition of mesh areas by 92% and 5 95%, respectively; of vessel length by 96% and 98% vs SU11274-treated cells (P<0.001; Fig. 4D ). antiplasmin, pigment epithelium derived factor), member 1] (28), and was increased by 30%. The 17 drug-modulation of these cytokines was also confirmed by real time RT-PCR analysis of SU11274-18 treated vs untreated MMECs ( Supplementary Fig. S4A ).
19
Data suggest that the HGF/cMET pathway is implicated in regulating the overangiogenic MMECs 20 profile. The MMECs proteome was studied following treatment with SU11274 alone or combined with 24 bortezomib or lenalidomide vs untreated cells (control). At least three 2-DE-gels were run per 1 fold changes vs control) upon treatment with SU11274 alone (Fig. 5B ) and in combination 2 ( Supplementary Fig. S3 ): four angiogenic proteins ( Supplementary Table S2 ), i.e., annexin A4 3 (ANXA4, #2), prohibitin (PHB, #3), peroxiredoxin-6 (PRDX6, #10), and annexin A2 (ANXA2, 4 #12), which govern cell shape and migration, were downregulated; while one protein, i.e., calpain 5 small subunit 1 (CPNS1, #1), which regulates cell senescence, was upregulated. A real time RT-6 PCR for these last five proteins showed a symmetric gene modulation following the cMET 7 inhibition ( Supplementary Fig. S4B ). When CAMs were implanted with a gelatine sponge soaked with the MMECs CM, many newly-11 formed capillaries converging radially toward the sponge in a "spoked-wheel" pattern were seen 12 (vessel count = 27 ± 4 vs 8 ± 3 of physiological angiogenesis in serum-free medium; P<0.001; Fig.   13 6, panels a and b). In contrast, MMECs treated with SU11274 were poorly angiogenic (16 ± 2; 14 panel c), and even less with SU11274 plus bortezomib or lenalidomide in a statistically significant 15 fashion (7 ± 2 and 8 ± 3, respectively; P<0.001; Fig. 6, panels d and e ). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158/1078-0432.CCR-14-0847 1 antiangiogenic management of MM patients. This pathway governes the tumor cell scattering, 2 hence it regulates cell motility and metastatic spread (33). HGF is released by mesenchyma-derived 3 cells, whereas cMET is expressed by several cell types, including vascular endothelial cells (34) and 4 accessory cells (pericytes) (35). Activation of cMET in tumors most often occurs through ligand 5 dependent autocrine or paracrine mechanisms. Either HGF is released from the surrounding stromal 6 cells, resulting in a constitutive paracrine cMET activation (11); or coexpression of HGF and cMET 7 leads to autocrine activation, as found in carcinomas, sarcomas, gliomas and B cell tumors (8, 9, 8 36). The HGF/cMET pathway is also involved in the MM pathogenesis: its paracrine and autocrine 9 activation have been found in both PCs and microenvironment cells (9, 10).
10
The HGF/cMET pathway plays a key role in angiogenesis, since it stimulates ECs both directly and 11 indirectly by enhancing the expression of the VEGF-A/VEGFR2 pathway and downregulating 12 thrombospondin 1, an angiogenesis inhibitor (7). Here, we show that the HGF/cMET pathway is Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158 /1078 1 the intracrine loop is sufficient to mediate cell adhesion and spreading. On the other hand, treatment 2 of cells with the anti-cMET Ab (Fig. 3C ) or with SU11274 ( Fig. 4C ) is able to inhibit both 3 autocrine and intracrine loops, hence MMECs adhesion and spreading, which supports a role of 4 HGF/cMET pathway also in these cell functions. 5 We found that the cMET pathway is overactivated in drug-resistant MM cell lines as well as in PCs Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 11, 2014; DOI: 10.1158 /1078 cMET inhibitor also downregulates angiogenic proteins, such as ANXA2 (43) 23 CAMs were incubated with gelatine sponges loaded with serum-free medium (physiological
